Cantor Fitzgerald Reiterates Overweight on Axsome Therapeutics, Raises Price Target to $125

Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target from $104 to $125.

Benzinga · 12/30/2019 20:36

Cantor Fitzgerald analyst Charles Duncan reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and raises the price target from $104 to $125.